Flecainidum [Inn-Latin] en es it fr

Flecainidum [Inn-Latin] Brand names, Flecainidum [Inn-Latin] Analogs

Flecainidum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Flecainidum [Inn-Latin] Chemical_Formula


Flecainidum [Inn-Latin] RX_link


Flecainidum [Inn-Latin] fda sheet

Flecainidum [Inn-Latin] msds (material safety sheet)


Flecainidum [Inn-Latin] Synthesis Reference

No information avaliable

Flecainidum [Inn-Latin] Molecular Weight

414.343 g/mol

Flecainidum [Inn-Latin] Melting Point

No information avaliable

Flecainidum [Inn-Latin] H2O Solubility

48.4 mg/mL at 37oC (acetate form)

Flecainidum [Inn-Latin] State


Flecainidum [Inn-Latin] LogP


Flecainidum [Inn-Latin] Dosage Forms

Tablet (50, 100, 150 mg)

Flecainidum [Inn-Latin] Indication

For the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin.

Flecainidum [Inn-Latin] Pharmacology

Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics.

Flecainidum [Inn-Latin] Absorption

Nearly complete following oral administration.

Flecainidum [Inn-Latin] side effects and Toxicity

Oral LD50 is 50-498 mg/kg in rat. Symptoms of overdose include nausea and vomiting, convulsions, hypotension, bradycardia, syncope, extreme widening of the QRS complex, widening of the QT interval, widening of the PR interval, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, and cardiac arrest.

Flecainidum [Inn-Latin] Patient Information

No information avaliable

Flecainidum [Inn-Latin] Organisms Affected

Humans and other mammals